文献速递精神分裂症与精神病性障碍

难治性精神分裂症的多巴胺功能障碍与兴奋/抑制失衡及新型神经调控治疗

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.
PubMed 文献 · Mol Psychiatry · 2022-04-20

本文综述难治性精神分裂症(TRS)的神经生物学病理生理机制,重点涉及多巴胺能、谷氨酸能和GABA能通路,并讨论现有及有前景的治疗尤其是神经调控的局限与潜力,最后提出整合多视角的多变量分析以推动精准医学和闭环神经调控。

要点

  • 约三分之一患者对非氯氮平抗精神病药阳性症状改善不足,其中约一半对氯氮平、电休克或其他增效策略反应不佳。
  • TRS病理生理涉及多巴胺能、谷氨酸能和GABA能通路,以及兴奋/抑制失衡。
  • 神经调控(电休克、重复经颅磁刺激、经颅直流电刺激、深部脑刺激)具有治疗潜力。

核心结论

  • TRS病理生理复杂异质,需整合多巴胺功能障碍与兴奋/抑制失衡等多视角的多变量分析以推动精准医学和闭环神经调控。

研究设计与样本

  • 综述,回顾TRS神经生物学病理生理、现有及有前景治疗,并提出未来研究方向。

主要发现

  • 约三分之一精神分裂症患者对非氯氮平抗精神病药阳性症状改善不足。
  • 上述患者中约一半对氯氮平、电休克或其他增效策略反应不佳。
  • TRS涉及多巴胺能、谷氨酸能和GABA能通路及兴奋/抑制失衡。

临床怎么用

  • 神经调控包括电休克、重复经颅磁刺激、经颅直流电刺激和深部脑刺激,具有治疗潜力。
  • 多变量分析可揭示常规统计无法获得的TRS异质性,进而引导针对检测到的病理生理的闭环神经调控精准医学方法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third of patients do not show adequate improvement in positive symptoms with non-clozapine antipsychotics. Additionally, approximately half of them show poor response to clozapine, electroconvulsive therapy, or other augmentation strategies. However, the development of novel treatment for these conditions is difficult due to the complex and heterogenous pathophysiology of treatment-resistant schizophrenia (TRS). Therefore, this review provides key findings, potential treatments, and a roadmap for future research in this area. First, we review the neurobiological pathophysiology of TRS, particularly the dopaminergic, glutamatergic, and GABAergic pathways. Next, the limitations of existing and promising treatments are presented. Specifically, this article focuses on the therapeutic potential of neuromodulation, including electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation. Finally, we propose multivariate analyses that integrate various perspectives of the pathogenesis, such as dopaminergic dysfunction and excitatory/inhibitory imbalance, thereby elucidating the heterogeneity of TRS that could not be obtained by conventional statistics. These analyses can in turn lead to a precision medicine approach with closed-loop neuromodulation targeting the detected pathophysiology of TRS.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wada M, Noda Y, Iwata Y, et al. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Mol Psychiatry. 2022. PMID: 35444257. doi:10.1038/s41380-022-01572-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。